PTGX (Protagonist Therapeutics) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PTGX Protagonist Therapeutics Inc PTGX
47 GF Score
Price $138.31
GF Value $67.43
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Protagonist Therapeutics FFO per Share?

FFO per Share only applies to REITs.

PTGX
47GF Score
Protagonist Therapeutics Inc PTGX
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Protagonist Therapeutics (PTGX) Overvalued in 2026?

Based on GuruFocus' analysis, Protagonist Therapeutics stock appears to be overvalued. The current stock price of $138.31 is trading 105.1% above its estimated GF Value™ of $67.43. GuruFocus considers Protagonist Therapeutics to be Significantly Overvalued.

Key valuation signals for PTGX:

  • FFO per Share:
  • GF Value™: $67.43 vs. price of $138.31 (105.1% above fair value)
  • GF Score™: 47/100 with 8 warning signs

No single metric tells the full story. See the PTGX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Protagonist Therapeutics Business Description

Address 7707 Gateway Boulevard, Suite 140, Newark, CA, USA, 94560
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.
47GF Score

Get the complete analysis for PTGX

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$138.31
Price
$67.43
GF Value